JP2025506142A5 - - Google Patents
Info
- Publication number
- JP2025506142A5 JP2025506142A5 JP2024547222A JP2024547222A JP2025506142A5 JP 2025506142 A5 JP2025506142 A5 JP 2025506142A5 JP 2024547222 A JP2024547222 A JP 2024547222A JP 2024547222 A JP2024547222 A JP 2024547222A JP 2025506142 A5 JP2025506142 A5 JP 2025506142A5
- Authority
- JP
- Japan
- Prior art keywords
- ctla
- cancer
- bispecific molecule
- antibody
- drug conjugate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263308903P | 2022-02-10 | 2022-02-10 | |
| US63/308,903 | 2022-02-10 | ||
| US202263331370P | 2022-04-15 | 2022-04-15 | |
| US63/331,370 | 2022-04-15 | ||
| PCT/US2023/062265 WO2023154784A1 (en) | 2022-02-10 | 2023-02-09 | Methods for the use of a b7-h3 antibody-drug conjugate in combination with a pd-1 x ctla-4 bispecific molecule |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2025506142A JP2025506142A (ja) | 2025-03-07 |
| JP2025506142A5 true JP2025506142A5 (https=) | 2026-02-12 |
Family
ID=87565102
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024547222A Pending JP2025506142A (ja) | 2022-02-10 | 2023-02-09 | Ｂ７‐ｈ３抗体薬物複合体のｐｄ‐１×ｃｔｌａ‐４二重特異性分子との併用のための方法 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20250135022A1 (https=) |
| EP (1) | EP4476262A1 (https=) |
| JP (1) | JP2025506142A (https=) |
| KR (1) | KR20240141822A (https=) |
| AU (1) | AU2023219168A1 (https=) |
| CA (1) | CA3243899A1 (https=) |
| IL (1) | IL314863A (https=) |
| MX (1) | MX2024009780A (https=) |
| TW (1) | TW202342107A (https=) |
| WO (1) | WO2023154784A1 (https=) |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL260021B (en) * | 2015-12-14 | 2022-09-01 | Macrogenics Inc | Bispecific molecules that are immunoreactive for pd1 and ctla4 and methods for using them |
| GEP20227398B (en) * | 2016-04-15 | 2022-07-25 | Macrogenics Inc | Novel b7-h3 binding molecules, antibody drug conjugates thereof and usage thereof |
| WO2021247794A2 (en) * | 2020-06-03 | 2021-12-09 | Regents Of The University Of Minnesota | B7h3-targeting proteins and methods of use thereof |
-
2023
- 2023-02-09 JP JP2024547222A patent/JP2025506142A/ja active Pending
- 2023-02-09 KR KR1020247029092A patent/KR20240141822A/ko active Pending
- 2023-02-09 IL IL314863A patent/IL314863A/en unknown
- 2023-02-09 EP EP23753648.7A patent/EP4476262A1/en active Pending
- 2023-02-09 WO PCT/US2023/062265 patent/WO2023154784A1/en not_active Ceased
- 2023-02-09 MX MX2024009780A patent/MX2024009780A/es unknown
- 2023-02-09 US US18/836,888 patent/US20250135022A1/en active Pending
- 2023-02-09 CA CA3243899A patent/CA3243899A1/en active Pending
- 2023-02-09 AU AU2023219168A patent/AU2023219168A1/en active Pending
- 2023-02-10 TW TW112104872A patent/TW202342107A/zh unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023539715A5 (https=) | ||
| JP2018509182A5 (https=) | ||
| WO2021142039A1 (en) | Anti-psma antibodies, antibody drug conjugates, and methods of use thereof | |
| JP2012509259A5 (https=) | ||
| ES3054415T3 (en) | Anti-c-met antibody drug conjugates | |
| JP2023525320A5 (https=) | ||
| JP2023529640A (ja) | 治療用コンジュゲート | |
| TW202330040A (zh) | 抗ｈｅｒ２抗體藥物偶聯物和酪胺酸激酶抑制劑聯合在製備治療腫瘤的藥物中的用途 | |
| CN116712539A (zh) | 抗her2抗体药物偶联物和抗pd-1抗体联合在制备治疗肿瘤的药物中的用途 | |
| JPWO2021251459A5 (https=) | ||
| CN111278462A (zh) | 抗egfr抗体药物结合物(adc)和其用途 | |
| WO2018187158A1 (en) | Combination therapy of cancer with anti-endoglin antibodies and anti-programmed death receptor agents | |
| JP2025506142A5 (https=) | ||
| AU2003241024A1 (en) | Methods and compositions for radioimmunotherapy of brain and cns tumors | |
| JP2023536086A5 (https=) | ||
| US20250281654A1 (en) | Methods for treating cancer using combinations of epigenetic therapies and radioconjugate targeting agents | |
| WO2025151684A1 (en) | Antibody-auristatin drug conjugates and methods of making and using thereof | |
| WO2025113644A1 (zh) | Pd-l1结合分子与蛋白-药物偶联物的组合及其用途 | |
| JP2025503511A5 (https=) | ||
| KR20250096894A (ko) | 고안정성 친수성 연결 유닛을 갖는 아우리스타틴 약물 및 이의 접합체 | |
| KR20250048287A (ko) | 새로운 티올 환원제, 제조 방법 및 용도 | |
| TW202600174A (zh) | 抗體藥物偶聯物和抗ｅｇｆｒ抗體的聯合應用 | |
| WO2026086635A1 (zh) | 抗体或者抗体药物偶联物与其他治疗剂的组合用途 | |
| CN120774988A (zh) | 一种连接子、抗体药物偶联物及其制备方法 | |
| KR20250108097A (ko) | Egfr을 표적으로 하는 항체-약물 접합체를 이용한 비인두암 치료 |